A cost effective strategy of bevacizumab in treatment of primary ovarian cancer — A subset analysis of ICON 7 trial

J Chan,T Herzog,L Hu,T Kiet,B Monk,D Kapp,X Yu

doi:10.1016/j.ygyno.2011.12.037

A cost effective strategy of bevacizumab in treatment of primary ovarian cancer — A subset analysis of ICON 7 trial

J Chan, T Herzog + Show 5 more

https://doi.org/10.1016/j.ygyno.2011.12.037

Copy DOI

Journal: Gynecologic oncology	Publication Date: Mar 1, 2012
Citations: 2

Affiliation: UCSF Helen Diller Family Comprehensive Cancer Center, NewYork–Presbyterian Hospital, Creighton University, Stanford Medicine, University of Memphis

#Treatment Of Primary Ovarian Cancer #Addition Of Bevacizumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objective: A subset analysis of ICON 7 showed that the addition of bevacizumab (B) and maintenance bevacizumab (mB) to paclitaxel (P) and carboplatin (C) improved the overall survival of stage IIIC (suboptimal) and stage IV ovarian cancer after primary surgery. Given the expense of B, we evaluated the cost effectiveness of B in this subset of patients.

Full Text